Development of a high throughput drug screening assay for the detection of changes in tau levels -- proof of concept with HSP90 inhibitors
- PMID: 15974923
- DOI: 10.2174/1567205053585927
Development of a high throughput drug screening assay for the detection of changes in tau levels -- proof of concept with HSP90 inhibitors
Abstract
Therapeutic development for Alzheimer's disease has largely focused on the removal of beta amyloid because of its suggested role in the primary agent in initiating the disease process. However, with the recent discovery of mutations that result as pathologic buildup of tau in the absence of amyloid pathology, tau is beginning to be recognized as a potential target for drug discovery. We have developed a high-throughput drug screening method that allows for direct intracellular quantitation of tau protein species, enabling the fast, reliable detection of these changes. We have identified a family of small, blood brain barrier penetrant heat shock protein 90 inhibitors that significantly reduce tau protein levels in vitro. Western blot analysis demonstrated a clear inverse correlation between the tau levels and the increase in HSP27, HSP40 and HSP90. Modifications to this assay will further allow the specific analysis of pathologically relevant species. Using this assay, we have demonstrated that a class of HSP90 inhibitors is able to significantly lower intracellular tau levels most likely through induction of a heat shock response.
Similar articles
-
Targeting Hsp90 and its co-chaperones to treat Alzheimer's disease.Expert Opin Ther Targets. 2014 Oct;18(10):1219-32. doi: 10.1517/14728222.2014.943185. Epub 2014 Jul 29. Expert Opin Ther Targets. 2014. PMID: 25069659 Free PMC article. Review.
-
The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins.J Clin Invest. 2007 Mar;117(3):648-58. doi: 10.1172/JCI29715. Epub 2007 Feb 15. J Clin Invest. 2007. PMID: 17304350 Free PMC article.
-
Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors.J Med Chem. 2014 Nov 13;57(21):8718-28. doi: 10.1021/jm500823a. Epub 2014 Aug 29. J Med Chem. 2014. PMID: 25141341 Review.
-
Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer's disease.Prog Neurobiol. 2011 Jan;93(1):99-110. doi: 10.1016/j.pneurobio.2010.10.006. Epub 2010 Nov 5. Prog Neurobiol. 2011. PMID: 21056617 Review.
-
Binding of Hsp90 to tau promotes a conformational change and aggregation of tau protein.J Alzheimers Dis. 2009;17(2):319-25. doi: 10.3233/JAD-2009-1049. J Alzheimers Dis. 2009. PMID: 19363271
Cited by
-
Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases.Nat Rev Drug Discov. 2011 Dec 1;10(12):930-44. doi: 10.1038/nrd3453. Nat Rev Drug Discov. 2011. PMID: 22129991 Free PMC article. Review.
-
Model Hirano bodies protect against tau-independent and tau-dependent cell death initiated by the amyloid precursor protein intracellular domain.PLoS One. 2012;7(9):e44996. doi: 10.1371/journal.pone.0044996. Epub 2012 Sep 18. PLoS One. 2012. PMID: 23028730 Free PMC article.
-
Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression.Mol Neurodegener. 2006 Jul 26;1:6. doi: 10.1186/1750-1326-1-6. Mol Neurodegener. 2006. PMID: 16930453 Free PMC article.
-
Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity.J Pharmacol Exp Ther. 2010 Mar;332(3):849-57. doi: 10.1124/jpet.109.158436. Epub 2009 Nov 24. J Pharmacol Exp Ther. 2010. PMID: 19934398 Free PMC article.
-
Rous-Whipple Award Lecture. The Alzheimer's brain: finding out what's broken tells us how to fix it.Am J Pathol. 2005 Nov;167(5):1183-8. doi: 10.1016/s0002-9440(10)61206-0. Am J Pathol. 2005. PMID: 16251403 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous